SPRY – ars pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing =15 kg to <30 kg
ARS Pharmaceuticals (NASDAQ:SPRY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
ARS Pharmaceuticals (NASDAQ:SPRY) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use [Yahoo! Finance]
Form SCHEDULE 13G ARS Pharmaceuticals, Filed by: BlackRock, Inc.
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Scott Kathleen D.
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Karas Eric
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Fitzpatrick Alexander A
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Dorsey Brian
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.